Publications by authors named "Peter M Irving"

Claim this Profile
D
Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease.
Silvio Danese, Bruce E Sands, Brian G Feagan, Vipul Jairath, Remo Panaccione, Peter M Irving

Contemp Clin Trials Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age.
Adam S Faye, David T Rubin, Corey A Siegel, Millie D Long, Nabeel Khan, Peter M Irving

Inflamm Bowel Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment.
Remo Panaccione, Marc Ferrante, Iris Dotan, Julian Panés, Tadakazu Hisamatsu, Peter M Irving

Clin Gastroenterol Hepatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of PredictSURE IBD Assay in a Multinational Cohort of Patients With Inflammatory Bowel Disease.
Dahham Alsoud, Nurulamin M Noor, Lea Ann Chen, Vivian Abadom, Simon H C Anderson, Peter M Irving

United European Gastroenterol J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program.
Gary R Lichtenstein, Jessica R Allegretti, Edward V Loftus, Peter M Irving, Rupa Banerjee

Inflamm Bowel Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fecal loss of vedolizumab is associated with ulcerative colitis severity, lower serum vedolizumab levels, and rates of clinical response: results from the FAVOUR study.
Mark A Samaan, Georgina Cunningham, Samuel Hsiang Lim, Patrick Dawson, Sherine Hermangild Kottoor, Peter M Irving

J Crohns Colitis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programme.
María Chaparro, Remo Panaccione, Bruce E Sands, Peter M Irving, Martina Goetsch

BMJ Open Gastroenterol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Bruce E Sands, Geert D'Haens, David B Clemow, Peter M Irving, Jordan T Johns

Inflamm Bowel Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials.
Jean-Frédéric Colombel, Ana P Lacerda, Peter M Irving, Remo Panaccione, Walter Reinisch

Clin Gastroenterol Hepatol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor Necrosis Factor Drug Concentration Is Not Associated with Disease Outcomes in Pouchitis: A Retrospective, International Study.
Sailish Honap, Bénédicte Caron, Jacob E Ollech, Maya Fischman, Konstantinos Papamichael, Peter M Irving

Dig Dis Sci· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel Disease.
Hannah K Systrom, Victoria Rai, Siddharth Singh, Leonard Baidoo, Adam S Cheifetz, Peter M Irving

Am J Gastroenterol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of intestinal biopsy tissue preservation methods to facilitate large-scale mucosal microbiota research.
Nicola J Wyatt, Hannah Watson, Gregory R Young, Mary Doona, Ned Tilling, Peter M Irving

EBioMedicine· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis.
Séverine Vermeire, David T Rubin, Laurent Peyrin-Biroulet, Marla C Dubinsky, Miguel Regueiro, Peter M Irving

BMJ Open Gastroenterol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Bruce E Sands, Geert D'Haens, David B Clemow, Peter M Irving, Jordan T Johns

Inflamm Bowel Dis· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An evaluation of mirikizumab for the treatment of ulcerative colitis.
Christopher White, Peter M Irving

Expert Opin Biol Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review.
Peter M Irving, Peter Hur, Raju Gautam, Xiang Guo, Severine Vermeire

J Manag Care Spec Pharm· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: Post hoc longitudinal analysis of a randomized trial.
Stefan Schreiber, Geert D'Haens, Fraser Cummings, Peter M Irving, Byong Duk Ye

Dig Liver Dis· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stem Cells and Stem Cell-Derived Factors for the Treatment of Inflammatory Bowel Disease with a Particular Focus on Perianal Fistulizing Disease: A Minireview on Future Perspectives.
Amy L Lightner, Peter M Irving, Graham M Lord, Aline Betancourt

BioDrugs· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Laurent Peyrin-Biroulet, J Casey Chapman, Jean-Frederic Colombel, Flavio Caprioli, Geert D'Haens, Peter M Irving

N Engl J Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource.
Christina Kapizioni, Rofaida Desoki, Danielle Lam, Karthiha Balendran, Eman Al-Sulais, Peter M Irving

J Crohns Colitis· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
Neil Chanchlani, Simeng Lin, Claire Bewshea, Benjamin Hamilton, Amanda Thomas, Peter M Irving

Lancet Gastroenterol Hepatol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
Nurulamin M Noor, James C Lee, Simon Bond, Francis Dowling, Biljana Brezina, Peter M Irving

Lancet Gastroenterol Hepatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial.
James O Lindsay, Daniel Hind, Lizzie Swaby, Hannah Berntsson, Mike Bradburn, Peter M Irving

Lancet Gastroenterol Hepatol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining predictors of responsiveness to advanced therapies in Crohn's disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine.
Nicola J Wyatt, Hannah Watson, Carl A Anderson, Nicholas A Kennedy, Tim Raine, Peter M Irving

BMJ Open· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis